Tuesday, June 23, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Chimeric Antigen Receptor T-Cell Therapy


Krishna Komanduri, MD
Sylvester Comprehensive Cancer Center
Miller School of Medicine
University of Miami Health System
Miami, Florida

Nikhil C Munshi, MD
Kraft Family Chair
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Sattva S Neelapu, MD
Professor and Deputy Chair
Department of Lymphoma and Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Tiffany Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Elizabeth Zerante, MS, AGACNP-BC
APN Inpatient Hematopoietic Cellular
Therapy Service
University of Chicago Medicine
Chicago, Illinois


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Biologic rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in B-cell lymphomas, acute lymphoblastic leukemia and multiple myeloma (MM)
  • Overview of CAR T-cell therapy; selection of patients and timing of administration
  • Existing and emerging efficacy data from clinical trials of approved (axicabtagene ciloleucel, tisagenlecleucel) and investigational (lisocabtagene maraleucel) CAR T-cell therapies directed at CD19 for patients with relapsed/refractory B-cell lymphomas; optimal integration into treatment algorithms
  • FDA approval of tisagenlecleucel for pediatric and young adult patients with acute lymphoblastic leukemia that is refractory or in second or later relapse; ongoing clinical investigation of CAR T-cell therapy in adult populations
  • Published efficacy and safety outcomes with and ongoing investigation of B-cell maturation antigen-targeted CAR T-cell therapies for MM; emerging results from the pivotal Phase II KarMMa study of idecabtagene vicleucel for relapsed/refractory MM
  • Spectrum, frequency, timing and severity of adverse events associated with CAR T-cell therapies, including cytokine release syndrome and neurologic toxicities; counseling patients and families about potential adverse events; effective management strategies

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Develop an understanding of the biologic rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences between commercially available and investigational products.
  • Appraise existing and emerging efficacy data from clinical trials of approved and investigational CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
  • Understand how CAR T-cell therapies have been evaluated for acute lymphoblastic leukemia, and consider how approved platforms may be appropriately integrated into patient care.
  • Appreciate available data documenting the activity of CAR T-cell therapy directed against B-cell maturation antigen, and apply this knowledge to identify patients with multiple myeloma who may be appropriate for this approach as part of a clinical trial.
  • Recognize adverse events and other common side effects associated with approved and investigational CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.
  • Recall the scientific rationale for and new data supporting the ongoing investigation of novel applications of CAR T-cell therapy, and counsel appropriately selected patients about study participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/CART/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr KomanduriAdvisory Committee: Kiadis Pharma; Consulting Agreements: Autolus Therapeutics, Celgene Corporation, Helocyte Inc, Incyte Corporation, Kadmon, Kite, A Gilead Company, Novartis, Takeda Oncology; Contracted Research: Autolus Therapeutics, Celgene Corporation, Incyte Corporation, Kite, A Gilead Company, Novartis. Dr MunshiConsulting Agreements: AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, BeiGene, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep. Dr NeelapuAdvisory Committee and Consulting Agreements: Adicet Bio, Allogene Therapeutics, Celgene Corporation, Incyte Corporation, Kite, A Gilead Company, Kuur Therapeutics, Legend Biotech, Merck, Novartis, Pfizer Inc, Precision BioSciences, Unum Therapeutics; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Allogene Therapeutics, Bristol-Myers Squibb Company, Cellectis, Karus Therapeutics, Kite, A Gilead Company, Merck, Poseida Therapeutics, Precision BioSciences, Unum Therapeutics. Dr RichardsAdvisory Committee: Celgene Corporation, GlaxoSmithKline, Takeda Oncology; Consulting Agreements: Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Takeda Oncology. Ms ZeranteSpeakers Bureau: Cancer Treatment Centers of America.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Celgene Corporation, Kite, A Gilead Company, and Novartis.